Aroner, Sarah A.
Furtado, Jeremy D.
Sacks, Frank M.
Tsai, Michael Y.
Mukamal, Kenneth J.
McClelland, Robyn L.
Jensen, Majken K.
Funding for this research was provided by:
National Center for Research Resources (UL1-TR-001079)
American Diabetes Association (1-15-JF-30)
William F. Milton Fund, Harvard Medical School
Roche Pharmaceuticals
National Heart, Lung, and Blood Institute (R21 HL091217)
National Institute of Diabetes and Digestive and Kidney Diseases (T32 DK 007703)
Article History
Received: 22 June 2018
Accepted: 7 February 2019
First Online: 4 April 2019
Duality of interest
: Roche Pharmaceuticals provided unrestricted funding for the development of the novel apoA-I/apoC-III ELISA and had no role in the design of the study, data collection, analyses or report. Harvard University holds a patent for the measurement of HDL subspecies by apoC-III where MKJ, JDF and FMS are named co-inventors.
Free to read: This content has been made available to all.